Avian Influenza Vaccine Efficacy Project AIVEP OSROEGY801USA

1
Avian Influenza Vaccine Efficacy Project (AIVEP)
(OSRO/EGY/801/USA)
Jointly implemented by NLQP and FAO
Strategic review (22-23/June/ 2009)
2
Strengthen capacity building

• Task force
• Provisional laboratories
• Satellite labs.

3
(No Transcript)
4

• Current situation

5
Epidemic curve (passive and active surveillance)
February 2006 till June 2009
1st Wave
2nd Wave
3rd Wave
4th Wave
2009
2006
2007
2008
6
AI situation in farms and backyard (2006 2007
2008-2009 )
1 slaughter house 4 check points 89 LBM
4 LBM 4 bird shops 3 check points
1 vendor
7
Project Objectives

• Identification of Circulating HPAI H5N1 Strains
  and select an Egyptian seed vaccinal strains.
• Evaluation of currently available/used vaccines
  against the identified isolates.

8
Partners

• South East Poultry Research Lab (SEPRL), USA.
• Erasmus University Medical Centre, The
  Netherlands.
• Naval Medical Research Unit 3 (NAMRU-3), USA.
• Central Lab for Evaluation of Veterinary
  Biologicals (CLEVB), Egypt.

9
Outputs
1 Identifying all AI isolates available
1- Screening and evaluation of genetic and
antigenic variants among existing field strains
(2006 - Early 2008)
2- Intensify HPAI Field sample collection and
evaluation of genetic and antigenic variants
among (Mid 2008- 2009) isolates
2 Selection of Variants for Challenge Studies
Challenge Testing of Antigenic Variants and
Existing Vaccines
Effective
Non effective
10
Work Activities
1- Intensify HPAI Field sample
3- Isolation and propagation of positive samples
2- diagnosis and detection of AI by using RRT-PCR
4- Sequence analysis evaluation of genetic
variants
5- Genetic cartography evaluation of antigenic
variants
6- Challenge testing Against the Current used
seed vaccine
Effective vaccine
Non Effective vaccine
11
Progress to date1.a Screening and evaluation of
genetic and antigenic variants among existing
field strains
12
Progress (Cont)
378 isolates
13
Progress (Cont)1.a.02 Sequencing and
phylogenetic analysis
72 isolates
34 isolates
14
Progress (Cont)1.a.02 Sequencing and
phylogenetic analysis
58 isolates
39 isolates
Under submission and acceptance from gene bank 32
HA gene and 17 NA gene from 2009
15
Progress (Cont)1.a.06 Assessment of Biosecurity
and Biosafety of Laboratory and Lab Operations
16
Progress (Cont)1.b Intensified HPAI Field
Isolate Collection
17
Progress (Cont)

• NLQP started its activities while in parallel
  processing administrative matters to avoid any
  delay in implementation.
• Two major LOAs prepared and signed between
• ERSMUS and FAO
• SEPRL and FAO
• All procurement of Equipment and consumables
  completed but not delivered yet. (delayed).
• Training arrangement finalized with SEPRL 5
  analysts (April and May 2009).
• Training arrangement finalized with NAMRU-3
  scheduled for the next month.

18
Progress (Cont.)

• Procurement of LIMS required additional
  consultation
• A project overview was published on the OFFLU web
  site http//www.offlu.net/OFFLU20Site/Egypt20Pro
  ject.pdf

19
Conclusion

• The project activities are implemented
  satisfactory.

20
Main Challenges and Response

• USAID grant for NLQP not yet transferred
  (finalized and waiting money transfer)
• All procurement of Equipment and consumables
  completed through FAO delayed.
• SAIDR Surveillance activities are reduced due to
  closure of LBM

21
Strategic plan for the project second year

• The project will continue to be implemented as
  previously planned.

22
Future urgent requirements for the project
extension

• Use the selected strain for Vaccine production
  through applying the Revere Genetics technology.
• Transfer of Revere Genetic Knowledge to NLQP for
  continuous update of virus strain depending on
  the recent mutation history and vaccination
  breakage.
• Establishment new BSL3 diagnostic laboratory and
  animal facility (facility building , equipment
  and training).
• Upgrade the building capacity of NLQP to become a
  Middle East OIE /FAO regional reference
  laboratory for HPAI, Emerging Infectious Diseases
  (EIDs) and zonoses with pandemic potentials

23
Thank You